MANAGEMENT OF NADIVRANA WITH SPECIAL REFERENCE TO PILONIDAL SINUS BY TWO TYPES OF VARTIS.
Phase 2
- Conditions
- Health Condition 1: L059- Pilonidal cyst and sinus without abscess
- Registration Number
- CTRI/2022/08/044894
- Lead Sponsor
- Dr Prasadshakti G Gannur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients presenting with classical signs and symtoms of nadivrana pain,discharge and a sinus in intergluteal region.
2.The age group between 16-60yrs
3.Both gender.
Exclusion Criteria
1.Congenital sinus
2.Pilonidal sinus with systemic diseas DM,Bleedig disorder, AIDS,Tuberculosis Actinomycosis.
3.Osteomyelitis followed by sinus
4.Patient having Neoplastic Sinus
5.If the sinus tract is more than10 cm
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ASSESSMENT CRITERIA: <br/ ><br> <br/ ><br>Subjective parameters. <br/ ><br>1 Pain-is asseed on visual analog scale. <br/ ><br>2 Burning sensation <br/ ><br>3 Itching sensation. <br/ ><br>Objective parameters <br/ ><br>4Discharge <br/ ><br>5Induration <br/ ><br>6Length of the tract <br/ ><br>Timepoint: Patient is assessed for above said parameters on 6th weeks. The observations will be recorded in the proforma of case sheet. <br/ ><br>Management is terminated after 6 weeks of the commencement of the therapy and to check the recurrence of the disease 3 months follow up will be done fortnightly. <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method Incidence of the Patients with classical signs and symtoms of nadivrana (pilonidal sinus) <br/ ><br> in the OPD and <br/ ><br>IPD section at SRHI J G COOPERATIVE <br/ ><br>HOSPITAL SOCIETYS AYURVEDIC MEDICAL <br/ ><br>COLLEGE HOSPITAL AND RESEARCH <br/ ><br>CENTRE will be Discussed with the points <br/ ><br>related with the Age, Sex, Occupation, Diet, etc.Timepoint: Patient is assessed for above said parameters on every 7th day during treatment schedule ,up to 6 weeks. The observations will be recorded in the proforma of case sheet. <br/ ><br>Management is terminated after 6 weeks of the commencement of the therapy and to check the recurrence of the disease 3 months follow up will be done fortnightly. <br/ ><br>